If you carry variants associated with lower receptor sensitivity, your provider may recommend starting with tirzepatide or a dual-compound approach instead
00:00:57 Narrator With that, Lets get started 00:01:05 Vickie Danaher We know that the injectable GLP-1 medications have become pretty popular over the last few years for obesity, type 2 diabetes, and other conditions, but the fact that we now have an oral GLP-1 agonist for weight loss is a big change
Holman, UKPDS Study Group: risk factors for renal dysfunction in type 2 diabetes: U.K
Thoene J, Lemons R, Anikster Y, Mullet J, Paelicke K, Lucero C, Gahl W, Schneider J, Shu SG, Campbell HT (1999) Mutations of CTNS causing intermediate cystinosis
Injection technique with compounded vials Boothwyn tirzepatide arrives in vials, not pens
A mixture between these two is termed semisodium valproate